Using our AI model trained on historical data, we generated a 12‑month forecast for BioCryst Pharmaceuticals Inc. (BCRX) stock. The model estimates a median target price of 6.59—ranging from a low of 3.21 to a high of 10.11—which suggests a decrease of -22.83% compared to the current price of 8.54.